Decoding 10 Analyst Evaluations For CG Oncology
Decoding 10 Analyst Evaluations For CG Oncology
解碼 CG 腫瘤學的 10 項分析師評估
In the latest quarter, 10 analysts provided ratings for CG Oncology (NASDAQ:CGON), showcasing a mix of bullish and bearish perspectives.
在最近一個季度中，10位分析師爲CG Oncology（納斯達克股票代碼：CGON）提供了評級，顯示了看漲和看跌的觀點。
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
下表簡要概述了他們最近的評級，重點介紹了過去30天中情緒的變化，並將其與前幾個月進行了比較。
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $64.7, with a high estimate of $75.00 and a low estimate of $42.00. Marking an increase of 50.47%, the current average surpasses the previous average price target of $43.00.
分析師對12個月目標股價的評估提供了更多見解，顯示平均目標股價爲64.7美元，最高估計爲75.00美元，低估值爲42.00美元。目前的平均價格上漲了50.47％，超過了之前的平均目標股價43.00美元。
Exploring Analyst Ratings: An In-Depth Overview
探索分析師評級：深入概述
A comprehensive examination of how financial experts perceive CG...
對金融專家如何看待...
登入免費觀看全文
登入/註冊